Prevalence of Cannabis Use for Pain Management in Quebec: A Post-Legalization Estimate Among Generations Living with Chronic Pain

M. Godbout-Parent, H. L. Nguena Nguefack, A. Angarita-Fonseca, C. Audet, A. Bernier, G. Zahlan, N. Julien, M. G. Pagé, L Guenette, L. Blais, A. Lacasse: Prevalence of Cannabis Use for Pain Management in Quebec: A Post-Legalization Estimate Among Generations Living with Chronic Pain. In: Canadian Journal of Pain, 2022.

Abstract

Background
While medical cannabis has been legal in Canada since 2001, recreational cannabis was legalized in October 2018 which has led to a widespread increase in the accessibility of cannabis products.
Aims
This study aimed to estimate the prevalence of cannabis use among adults living with chronic pain (CP) and investigate the relationship between age and cannabis use for CP management.
Methods
A cross-sectional analysis of the COPE Cohort dataset, a large Quebec sample of 1,935 adults living with CP, was conducted. Participants completed a web-based questionnaire in 2019 that contained three yes/no questions about past-year use of cannabis (i.e., for pain management, management of other health-related conditions, recreational purposes).
Results
Among the 1,344 participants who completed the cannabis use section of the questionnaire, the overall prevalence of cannabis use for pain management was 30.1% (95%CI:27.7-32.7). Differences were found between age groups with the highest prevalence among participants aged ≤26 years (36.5%) and lowest for those aged ≥74 years (8.8%). A multivariable logistic model revealed that age, region of residence, generalized pain, use of medications or non-pharmacological approaches for pain management, alcohol/drug consumption, and smoking were associated with the likelihood of using cannabis for pain management.
Conclusions
Cannabis is a common treatment for the management of CP, especially in younger generations. The high prevalence of use emphasizes the importance of better knowledge translation for people living with CP, rapidly generating evidence regarding the safety and efficacy of cannabis, and clinicians’ involvement in supporting people who use cannabis for pain management.

BibTeX (Download)

@article{JA0422,
title = {Prevalence of Cannabis Use for Pain Management in Quebec: A Post-Legalization Estimate Among Generations Living with Chronic Pain},
author = {M. Godbout-Parent and H. L. Nguena Nguefack and A. Angarita-Fonseca and C. Audet and A. Bernier and G. Zahlan and N. Julien and M. G. Pag\'{e} and L Guenette and L. Blais and A. Lacasse},
url = {https://www.tandfonline.com/doi/epub/10.1080/24740527.2022.2051112?needAccess=true, CJP},
doi = {https://doi.org/10.1080/24740527.2022.2051112},
year  = {2022},
date = {2022-03-30},
urldate = {2022-03-30},
journal = {Canadian Journal of Pain},
abstract = {Background
While medical cannabis has been legal in Canada since 2001, recreational cannabis was legalized in October 2018 which has led to a widespread increase in the accessibility of cannabis products.
Aims
This study aimed to estimate the prevalence of cannabis use among adults living with chronic pain (CP) and investigate the relationship between age and cannabis use for CP management.
Methods
A cross-sectional analysis of the COPE Cohort dataset, a large Quebec sample of 1,935 adults living with CP, was conducted. Participants completed a web-based questionnaire in 2019 that contained three yes/no questions about past-year use of cannabis (i.e., for pain management, management of other health-related conditions, recreational purposes).
Results
Among the 1,344 participants who completed the cannabis use section of the questionnaire, the overall prevalence of cannabis use for pain management was 30.1% (95%CI:27.7-32.7). Differences were found between age groups with the highest prevalence among participants aged ≤26 years (36.5%) and lowest for those aged ≥74 years (8.8%). A multivariable logistic model revealed that age, region of residence, generalized pain, use of medications or non-pharmacological approaches for pain management, alcohol/drug consumption, and smoking were associated with the likelihood of using cannabis for pain management.
Conclusions
Cannabis is a common treatment for the management of CP, especially in younger generations. The high prevalence of use emphasizes the importance of better knowledge translation for people living with CP, rapidly generating evidence regarding the safety and efficacy of cannabis, and clinicians’ involvement in supporting people who use cannabis for pain management.},
keywords = {2022, Chronic Pain, Middle Author, Pharmacoepidemiology},
pubstate = {published},
tppubtype = {article}
}
PHP Code Snippets Powered By : XYZScripts.com